Know Cancer

or
forgot password

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer


Phase 1
18 Years
N/A
Not Enrolling
Female
Advanced Breast Cancer

Thank you

Trial Information

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer


For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:



- Female with advanced breast cancer previously treated with a taxane and an
anthracycline

- No pleural or pericardial effusion

- Not receiving anticoagulants

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To identify major toxicities

Outcome Time Frame:

throughout the study

Safety Issue:

Yes

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

United States: Food and Drug Administration

Study ID:

CA180-004

NCT ID:

NCT00452673

Start Date:

June 2007

Completion Date:

October 2012

Related Keywords:

  • Advanced Breast Cancer
  • Breast Neoplasms

Name

Location

City of Hope National Medical CenterLos Angeles, California  91010
Seattle Cancer Care AllianceSeattle, Washington  98109
New York Presbyterian HospitalNew York, New York  10021
Northwestern University Feinberg School of MedicineChicago, Illinois  60611